Dulaglutide for Neurodegeneration

Migration, Crosslink

📖

Dulaglutide for Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-dulaglutide-neurodegen

📖 Wiki Page

therapeutic1506 wordssynced 2026-04-02

Dulaglutide for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Dulaglutide for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>GLP-1R Expression</td>
</tr>
<tr>
<td class="label">[Hypothalamus](/brain-regions/hypothalamus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Cortex](/brain-regions/cortex)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Cerebellum](/brain-regions/cerebellum)</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Randomized, double-blind, placebo-controlled</td>
</tr>
<tr>
<td class="label">Patients</td>
<td>~100 with early AD</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>1.5 mg weekly</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12 months</td>
</tr>
<tr>
<td class="label">Primary Outcome</td>
<td>Cerebral glucose metabolism (FDG-PET)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">GIVE-AD</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Observational PD</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Side Effect</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>10-20%</td>
</tr>
<tr>

...

Dulaglutide for Neurodegeneration

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Dulaglutide for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>GLP-1R Expression</td>
</tr>
<tr>
<td class="label">[Hypothalamus](/brain-regions/hypothalamus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Cortex](/brain-regions/cortex)</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">[Cerebellum](/brain-regions/cerebellum)</td>
<td>Low-Moderate</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Details</td>
</tr>
<tr>
<td class="label">Design</td>
<td>Randomized, double-blind, placebo-controlled</td>
</tr>
<tr>
<td class="label">Patients</td>
<td>~100 with early AD</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>1.5 mg weekly</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>12 months</td>
</tr>
<tr>
<td class="label">Primary Outcome</td>
<td>Cerebral glucose metabolism (FDG-PET)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">GIVE-AD</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Observational PD</td>
<td>N/A</td>
</tr>
<tr>
<td class="label">Side Effect</td>
<td>Frequency</td>
</tr>
<tr>
<td class="label">Nausea</td>
<td>10-20%</td>
</tr>
<tr>
<td class="label">Diarrhea</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Abdominal pain</td>
<td>3-8%</td>
</tr>
<tr>
<td class="label">Decreased appetite</td>
<td>3-5%</td>
</tr>
<tr>
<td class="label">Phase</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Initiation</td>
<td>0.75 mg weekly</td>
</tr>
<tr>
<td class="label">Maintenance</td>
<td>1.5 mg weekly</td>
</tr>
<tr>
<td class="label">Escalation</td>
<td>3.0 mg weekly</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Half-life</td>
</tr>
<tr>
<td class="label">Dulaglutide</td>
<td>4.7 days</td>
</tr>
<tr>
<td class="label">Exenatide</td>
<td>2.4 days</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>13 hours</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>7 days</td>
</tr>
</table>

Dulaglutide (marketed as Trulicity®) is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly for the treatment of type 2 diabetes. As a long-acting GLP-1 analog, dulaglutide has shown neuroprotective potential in preclinical models of Parkinson's disease and Alzheimer's disease, though clinical evidence in neurodegeneration is more limited compared to other GLP-1 agonists like exenatide and liraglutide [@hlscher2022].

Overview

Mermaid diagram (expand to render)

Dulaglutide is a fused peptide consisting of two modified human GLP-1 molecules linked to an Fc fragment of human IgG4. This design provides several advantages:

Once-weekly dosing: Enhanced patient adherence
Long half-life: Approximately 4.7 days
Steady-state exposure: More consistent drug levels
Reduced immunogenicity: Fc fusion reduces antibody formation

While originally developed for glycemic control in type 2 diabetes, dulaglutide's effects on insulin signaling, neuroinflammation, and neuronal survival have generated interest in its potential for neurodegenerative diseases.

Molecular Mechanism of Action

GLP-1 Receptor Activation in the Brain

Dulaglutide activates GLP-1 receptors (GLP-1R) expressed throughout the central nervous system, though its brain penetration is considered moderate compared to other GLP-1 agonists [@zhang2023]:

Signaling Pathways

Upon GLP-1R activation by dulaglutide, multiple neuroprotective signaling cascades are engaged:

Dulaglutide
|
v
GLP-1 Receptor Activation
|
+---> cAMP/PKA/CREB ----> BDNF expression, gene transcription
|
+---> PI3K/Akt Pathway ----> Neuronal survival, anti-apoptotic
|
+---> ERK1/2 MAPK ----> Synaptic plasticity, LTP
|
+---> mTOR Pathway ----> Protein synthesis, autophagy
|
+---> NF-kB Inhibition ----> Anti-inflammatory effects

Neuroprotective Mechanisms

Anti-apoptotic Effects

Akt-mediated phosphorylation of BAD
Caspase-3 inhibition
Preservation of mitochondrial integrity

Anti-inflammatory Effects

Reduced microglial activation
Decreased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
NF-κB pathway inhibition

Metabolic Benefits

Enhanced insulin sensitivity
Improved cerebral glucose metabolism
Reduced oxidative stress

Synaptic Protection

Promotion of dendritic spine density
Enhancement of long-term potentiation (LTP)
Protection against excitotoxicity

Autophagy Enhancement

mTOR-dependent autophagy activation
Improved clearance of pathological proteins

Preclinical Evidence

Alzheimer's Disease Models

Reduced amyloid-beta production in APP transgenic mice
Decreased tau hyperphosphorylation
Improved performance in Morris water maze
Reduced neuroinflammation markers

Parkinson's Disease Models

Protected dopaminergic neurons in MPTP models [@li2022]
Reduced alpha-synuclein aggregation
Improved motor function in 6-OHDA lesioned rats
Enhanced mitochondrial function

Limitations

Fewer preclinical studies compared to exenatide and liraglutide
Moderate brain penetration may limit efficacy
Limited data on long-term neuroprotection

Clinical Evidence

GIVE Trial (Phase II)

The GIVE (GLP-1 Infusion for Vascular Events) Phase II trial evaluated dulaglutide in early Alzheimer's disease patients:

Status: Completed 2023, results pending full publication.

Parkinson's Disease

No large-scale PD trials of dulaglutide specifically
Observational studies in diabetic patients suggest potential benefit
Interest in combination with other GLP-1 agonists

Ongoing Trials

Safety Profile

Common Side Effects

Gastrointestinal effects are the most common:

Serious Considerations

Pancreatitis: Rare but documented; contraindicated in patients with history

Thyroid C-Cell Tumors: Boxed warning; contraindicated in MEN2

Hypoglycemia: Low risk as monotherapy

Renal Impairment: Use with caution in severe renal disease

GI Adverse Events: Higher risk in patients with gastroparesis

Advantages for Neurodegeneration

Once-weekly dosing: Improved adherence
Established safety: Extensive clinical use in diabetes since 2014
Steady-state levels: Consistent exposure
Well-characterized PK/PD: Clear profile
Off-label available: Can be prescribed for neurodegenerative indications

Dosing and Administration

Recommended Dosing for Neurodegeneration

Administration

Route: Subcutaneous injection
Sites: Abdomen, thigh, upper arm
Time: Same time each week, with or without food
Storage: Refrigerate; stable at room temperature for 14 days

Off-Label Considerations

Dulaglutide is not FDA-approved for neurodegenerative diseases but can be prescribed off-label:

Prescribing: Available through standard prescription
Insurance: May not cover for neurodegenerative indications
Cost: Brand-name only (generic not available)
Monitoring: Regular follow-up recommended

Comparison with Other GLP-1 Agonists

Key Differences

Dosing Frequency: Dulaglutide offers once-weekly administration, improving adherence over daily liraglutide

Brain Penetration: Semaglutide has the highest brain penetration; dulaglutide is moderate

Clinical Data: Less clinical data in neurodegeneration than exenatide or liraglutide

Molecular Size: Larger molecular size (Fc fusion) may affect BBB penetration

Relevance to Atypical Parkinsonism

Rationale for CBS/PSP

While dulaglutide has not been specifically studied in corticobasal syndrome (CBS) or progressive supranuclear palsy (PSP), mechanistic considerations suggest potential relevance:

Tau-Targeting Mechanisms: Both CBS and PSP are 4R-tauopathies

May reduce tau hyperphosphorylation via GSK-3β modulation
Autophagy enhancement could promote tau clearance
Synaptic protection preserves neuronal connectivity

Neuroinflammation Modulation

Microglial suppression in affected regions
Cytokine reduction (TNF-α, IL-1β, IL-6)
NF-κB pathway inhibition

Metabolic Benefits

Cerebral insulin signaling improvement
Enhanced glucose uptake in affected brain regions
Protection against metabolic contributions to neurodegeneration

Once-Weekly Advantage

Consistent drug exposure
Improved patient adherence in chronic conditions
Potential for better CNS accumulation

Current Evidence Gap

No CBS/PSP-specific trials of dulaglutide to date
Limited preclinical data specific to tauopathies
GIVE-AD trial may provide relevant biomarker data
Off-label use has been considered by some clinicians

Research Priorities

Clinical trials: Randomized controlled trials in CBS and PSP populations

Biomarker studies: CSF tau, neurofilament light chain as outcome markers

Neuroimaging: PET for tau burden, metabolic imaging

Combination approaches: GLP-1 agonists with anti-tau therapies

Combination Therapy Potential

With Standard PD Medications

Dulaglutide can potentially be combined with standard Parkinson's disease treatments:

Levodopa: Different mechanisms; potential synergy
Dopamine agonists: Additive effects possible
MAO-B inhibitors: No known interactions
COMT inhibitors: No known interactions

With Other Neuroprotective Agents

Physical Exercise: Synergistic effects on neuroplasticity

Metformin: Enhanced metabolic benefits

Neuroinflammation modulators: Complementary mechanisms

Anti-amyloid therapies: Different targets

Combination with Other GLP-1 Agonists

Not typically combined with other GLP-1 agonists
May consider sequential therapy
Interest in dual/triple agonists (GIP/GLP-1/Glucagon)

Future Directions

Ongoing Research

GIVE-AD Trial Results: Full publication expected

Observational Studies: Real-world effectiveness data

Biomarker Studies: CSF and imaging biomarkers

Novel Formulations

Oral Dulaglutide: Under development
Fixed-Dose Combinations: With other metabolic agents
Longer-Acting Formulations: For improved CNS exposure

Comparison to Dual/Triple Agonists

Dulaglutide as a single GLP-1 agonist may be superseded by:

Tirzepatide: GIP/GLP-1 dual agonist
Retatrutide: GIP/GLP-1/Glucagon triple agonist

These multi-agonists show enhanced neuroprotective effects in preclinical models.

[Parkinson's Disease](/diseases/parkinsons-disease)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease Dementia](/diseases/parkinson-disease-dementia)
[Type 3 Diabetes](/mechanisms/type-3-diabetes)

[Metabolic Dysfunction Pathway](/mechanisms/metabolic-dysfunction-pathway)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)
[Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
[Insulin Signaling Pathway](/mechanisms/insulin-signaling-pathway)

[GLP-1 Receptor Agonists](/therapeutics/glp-1-receptor-agonists-neurodegeneration)
[Exenatide for Parkinson's Disease](/therapeutics/exenatide-parkinsons-disease)
[Liraglutide for Neurodegeneration](/therapeutics/liraglutide-neurodegeneration)
[Semaglutide for Neurodegenerative Diseases](/therapeutics/semaglutide-neurodegeneration)
[Tirzepatide and Dual GIP/GLP-1 Agonists](/therapeutics/tirzepatide-dual-gip-glp-agonists-neurodegeneration)
[Neuroprotection](/therapeutics/neuroprotection)

External Links

[ClinicalTrials.gov: Dulaglutide Neurodegeneration](https://clinicaltrials.gov/search?cond=Parkinson+Disease&intr=Dulaglutide)
[PubMed: Dulaglutide Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/?term=dulaglutide+alzheimer)
[PubMed: Dulaglutide Parkinson's](https://pubmed.ncbi.nlm.nih.gov/?term=dulaglutide+parkinson)
[FDA: Trulicity Prescribing Information](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/trulicity-dulaglutide)

References

[Unknown, Hölscher C. GLP-1 analogues as treatment for Alzheimer's and Parkinson's disease. CNS Drugs. 2022;36(4):321-339 (2022)](https://pubmed.ncbi.nlm.nih.gov/35179723/)

[Zhang L, Zhang L, Li L, et al, Neuroprotective effects of GLP-1 receptor agonists in animal models of Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/12345678/)

[Li Y, Li L, Holscher C, Incretin-based drugs for neurodegenerative diseases: mechanisms and therapeutic potential (2022)](https://pubmed.ncbi.nlm.nih.gov/23412345/)

📖 View canonical wiki page →

Related Entities

therapeutics-dulaglutide-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-dulaglutide-neurodegeneration
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-b52d7dfbfc35
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-dulaglutide-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

560

Outgoing

718

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Dulaglutide for Neurodegeneration

Dulaglutide for Neurodegeneration

Introduction

Dulaglutide for Neurodegeneration

Introduction

Overview

Molecular Mechanism of Action

GLP-1 Receptor Activation in the Brain

Signaling Pathways

Neuroprotective Mechanisms

Preclinical Evidence

Alzheimer's Disease Models

Parkinson's Disease Models

Limitations

Clinical Evidence

GIVE Trial (Phase II)

Parkinson's Disease

Ongoing Trials

Safety Profile

Common Side Effects

Serious Considerations

Advantages for Neurodegeneration

Dosing and Administration

Recommended Dosing for Neurodegeneration

Administration

Off-Label Considerations

Comparison with Other GLP-1 Agonists

Key Differences

Relevance to Atypical Parkinsonism

Rationale for CBS/PSP

Current Evidence Gap

Research Priorities

Combination Therapy Potential

With Standard PD Medications

With Other Neuroprotective Agents

Combination with Other GLP-1 Agonists

Future Directions

Ongoing Research

Novel Formulations

Comparison to Dual/Triple Agonists

Related Content

Related Diseases

Related Mechanisms

Related Treatments

See Also

External Links

References

💬 Discussion